Medicare to Cover Genomic Health's Oncotype DX Breast Cancer Test for DCIS | GenomeWeb

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Friday that the national Medicare contractor for the firm's Oncotype DX breast cancer test has expanded Medicare coverage for the test.

The contractor, Palmetto GBA, has expanded its coverage policy for all qualified Medicare patients to include those with ductal carcinoma in situ, or DCIS, Genomic Health said. The coverage policy took effect May 8.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.